Inhibition of monoamine oxidase by d-methamphetamine. 1980

O Suzuki, and H Hattori, and M Asano, and M Oya, and Y Katsumata

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008694 Methamphetamine A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed. Deoxyephedrine,Desoxyephedrine,Desoxyn,Madrine,Metamfetamine,Methamphetamine Hydrochloride,Methylamphetamine,N-Methylamphetamine,Hydrochloride, Methamphetamine,N Methylamphetamine
D008928 Mitochondria Semiautonomous, self-reproducing organelles that occur in the cytoplasm of all cells of most, but not all, eukaryotes. Each mitochondrion is surrounded by a double limiting membrane. The inner membrane is highly invaginated, and its projections are called cristae. Mitochondria are the sites of the reactions of oxidative phosphorylation, which result in the formation of ATP. They contain distinctive RIBOSOMES, transfer RNAs (RNA, TRANSFER); AMINO ACYL T RNA SYNTHETASES; and elongation and termination factors. Mitochondria depend upon genes within the nucleus of the cells in which they reside for many essential messenger RNAs (RNA, MESSENGER). Mitochondria are believed to have arisen from aerobic bacteria that established a symbiotic relationship with primitive protoeukaryotes. (King & Stansfield, A Dictionary of Genetics, 4th ed) Mitochondrial Contraction,Mitochondrion,Contraction, Mitochondrial,Contractions, Mitochondrial,Mitochondrial Contractions
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D010627 Phenethylamines A group of compounds that are derivatives of beta- aminoethylbenzene which is structurally and pharmacologically related to amphetamine. (From Merck Index, 11th ed) Phenylethylamines
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D003010 Clorgyline An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE. Clorgilin,Chlorgyline,Clorgiline
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012642 Selegiline A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl. Deprenalin,Deprenil,Deprenyl,E-250,Eldepryl,Emsam,Humex,Jumex,L-Deprenyl,Selegiline Hydrochloride,Selegiline Hydrochloride, (R)-Isomer,Selegiline Hydrochloride, (R,S)-Isomer,Selegiline Hydrochloride, (S)-Isomer,Selegiline, (R)-Isomer,Selegiline, (R,S)-Isomer,Selegiline, (S)-Isomer,Selegyline,Yumex,Zelapar,E 250,E250

Related Publications

O Suzuki, and H Hattori, and M Asano, and M Oya, and Y Katsumata
May 1980, Biochemical pharmacology,
O Suzuki, and H Hattori, and M Asano, and M Oya, and Y Katsumata
August 1978, Biokhimiia (Moscow, Russia),
O Suzuki, and H Hattori, and M Asano, and M Oya, and Y Katsumata
January 1962, The Journal of pharmacology and experimental therapeutics,
O Suzuki, and H Hattori, and M Asano, and M Oya, and Y Katsumata
July 1982, Experientia,
O Suzuki, and H Hattori, and M Asano, and M Oya, and Y Katsumata
December 1985, Canadian journal of physiology and pharmacology,
O Suzuki, and H Hattori, and M Asano, and M Oya, and Y Katsumata
June 1984, Planta medica,
O Suzuki, and H Hattori, and M Asano, and M Oya, and Y Katsumata
October 1999, Archives of pharmacal research,
O Suzuki, and H Hattori, and M Asano, and M Oya, and Y Katsumata
April 2001, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
O Suzuki, and H Hattori, and M Asano, and M Oya, and Y Katsumata
August 1994, Biochemical Society transactions,
O Suzuki, and H Hattori, and M Asano, and M Oya, and Y Katsumata
January 1960, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!